Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.50 |
| ▸ | MME | P08473 | 5/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | KDM5C | P41229 | 3/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | KDM6B | O15054 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16314008 | 0.84 | TGFBR1 (0.52) | GNPATTGFBR1MMEFOLH1RIMKLA | |
| SCHEMBL22222603 | 0.83 | GNPAT (0.64) | GNPATMMEFOLH1RIMKLANAALAD2 | |
| SCHEMBL8418867 | 0.83 | NOD1 (0.56) | GNPATTGFBR1MMEFNTAFNTB | |
| SCHEMBL13654776 | 0.83 | CA2 (0.58) | GNPATMMEFOLH1RIMKLANAALAD2 | |
| SCHEMBL6270974 | 0.83 | FOLH1 (0.69) | GNPATFOLH1RIMKLANAALAD2KDM4E | |
| SCHEMBL1533825 | 0.83 | FOLH1 (0.69) | GNPATFOLH1RIMKLANAALAD2KDM4E | |
| SCHEMBL4572556 | 0.83 | CA2 (0.58) | GNPATMMEFOLH1RIMKLANAALAD2 | |
| SCHEMBL11279985 | 0.81 | TGFBR1 (0.48) | GNPATTGFBR1MMEFOLH1KDM4E | |
| SCHEMBL21314174 | 0.81 | MME (0.51) | GNPATTGFBR1MMEFNTAFNTB | |
| SCHEMBL9651941 | 0.81 | MME (0.51) | GNPATTGFBR1MMEFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497437-B2 | Modified Mullerian Inhibiting Substance (MIS) proteins and uses thereof for the treatment of diseases | THE GENERAL HOSPITAL CORPORATION | 2025-12-16 | — | — | US | disclosed |
| US-12208143-B2 | Compositions and methods for transport across the blood brain barrier | OPHIDION INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-12139542-B2 | Inhibitors of aortic carboxypeptidase-like protein (ACLP) | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240277812-A1 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION | THE GENERAL HOSPITAL CORPORATION (US) | 2024-08-22 | — | — | US | disclosed |
| US-11998590-B2 | Use of Mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation | THE GENERAL HOSPITAL CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4182300-A1 | IMPROVED METHOD FOR SYNTHESISING FUNCTIONALISED MERCAPTANS | ARKEMA FRANCE (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-20220387612-A1 | COMPOSITIONS AND METHODS FOR TRANSPORT ACROSS THE BLOOD BRAIN BARRIER | OPHIDION INC. | 2022-12-08 | — | — | US | disclosed |
| US-11376331-B2 | Compositions and methods for transport across the blood brain barrier | OPHIDION INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-4008339-A1 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION | The General Hospital Corporation (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3079712-B1 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION | MASSACHUSETTS GEN HOSPITAL (US) | 2022-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139542-B2 | Inhibitors of aortic carboxypeptidase-like protein (ACLP) | ENPEP, ADAM8, ADAM17 | GNPAT 881/4885TGFBR1 161/4885MME 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.